Cephalon Inc. and Mesoblast Limited Enter into Strategic Alliance to Develop and Commercialize Novel Therapeutic Products for Regenerative Medicine.
Cephalon Inc. and Mesoblast Limited announced they have entered into a strategic alliance to develop and commercialize novel adult Mesenchymal Precursor Stem Cell (MPC) therapeutics for degenerative conditions of the cardiovascular and central nervous systems. These conditions include Congestive Heart Failure, Acute Myocardial Infarction Parkinson's Disease, and Alzheimer's Disease. The alliance also extends to products for augmenting hematopoietic stem cell transplantation in cancer patients. Under the terms of the Development and Commercialization Agreement between the companies, in exchange for exclusive world-wide rights to commercialize specific products based on Mesoblast's proprietary adult stem cell technology platform, Cephalon will make an upfront payment to Mesoblast totaling $130 million ($30 million upon Mesoblast shareholder approval) and regulatory milestone payments of up to $1.7 billion. Mesoblast will be responsible for the conduct and expenses of certain Phase IIa clinical trials and commer
